Despite impressive data supporting HMA/Venetoclax, its application in younger, fit patients must be cautious. The pivotal VIALE-A trial excluded key subgroups like FLT3, core binding factor, and certain NPM1 patients, for whom intensive chemotherapy remains the standard.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

Similar to FLT3 inhibitors like midostaurin, which failed in the relapsed setting but succeeded upfront, menin inhibitors are expected to show dramatically better efficacy when combined with standard induction or HMA/Venetoclax in newly diagnosed patients.

While quizartinib's benefit is less pronounced in AML patients over 60, a specific genomic signature—the co-occurrence of FLT3-ITD, NPM1, and DNMT3A mutations—identifies a subset of older patients who derive a significant survival benefit, challenging age-based treatment decisions.

The Spanish KIWI trial showed a surprising survival benefit for quizartinib in FLT3-ITD negative AML. The benefit was greatest in patients with NPM1 and DNMT3A mutations, suggesting the drug's efficacy extends beyond its primary target through other mechanisms.

Standard cytogenetics miss complex genetic rearrangements. Advanced techniques like Optical Genome Mapping (OGM) are identifying "cryptic" fusions (e.g., involving KMT2A, NUP98) in patients who appear to be wild-type. This expands the eligible patient pool for menin inhibitors beyond those with classic mutations.

A key advantage of the FLT3 inhibitor quizartinib over midostaurin is its demonstrated survival benefit in FLT3-ITD positive AML patients who do not proceed to an allogeneic transplant in their first remission. This makes it a more robust upfront option for a broader patient group.

Risk stratification in CML is moving beyond BCR-ABL. Additional mutations like ASXL1 are now known to predict poorer outcomes and reduced response to asciminib, while others like GATA2 are favorable, pushing for routine, broader genetic sequencing at diagnosis to personalize therapy.

Cellcuity's drug is effective in breast cancer patients without PIK3CA mutations (wild type). This challenges the dominant precision medicine model that requires a specific genetic marker, showing that a pathway's aberrant activity can be a sufficient therapeutic target on its own.